Insider Purchases: Inside the Buy

Tag: Gene Editing

A confident businesswoman holds a glowing blue DNA helix like a lightsaber, standing against a golden background with a rising stock chart and the Vertex Pharmaceuticals logo—symbolizing innovation, biotech strength, and market growth.

CEO Bought Shares of Vertex Pharmaceuticals (VRTX) A Bit Higher Back in August: Great Biotech At A Fair Price. Wait For Additional Pull-Back?

Vertex is more than cystic fibrosis drugs. With gene editing, pain relief, and even a potential T1D cure, the CEO’s insider buy raises one question: buy now or wait for additional pullback?

 

Read entire article

Tags: Biotech Innovation, Biotech Investing, Buy VRTX Stock, CEO Buys, CEO Conviction, CEO insider buying, CEO Stock Purchase, CEOBuyIn, CEOConfidence, Funanc1al, Funanc1al Edge, Funanc1al Investing, Gene editing, Growth at a reasonable price, Reshma Kewalramani, Type 1 diabetes cure, Vertex Pharmaceuticals, VRTX
A colorful digital illustration featuring Moderna's logo (MRNA) with a rising stock chart, symbolizing the biotech company's potential growth and innovation in gene-based therapies.

Moderna (MRNA): The Biotech Rollercoaster – Will This Gene Editor Reach the Top? 🎢💉

Moderna (MRNA) might be on the downhill since its peak in 2021, but its remarkable mRNA platform is fueling new therapeutic breakthroughs. With strong insider bets, a healthy pipeline, and institutional backing, Moderna could be an intriguing long-term play for investors. However, risks like intense competition and COVID sales deceleration remain. Should you bet on Moderna’s future or stay on the sidelines? Here’s what you need to know.

Read entire article

Tags: Biotech Investments, Biotech Stocks, Biotechnology, Biotechnology Innovation, COVID Vaccine, Gene Editing, healthcare stocks, Insider Purchases, Investment Insights, Moderna, Moderna CEO, mRNA, Paul Sagan, pharmaceutical stocks, Stephane Bancel